Muscarinic Acetylcholine Receptor Global Market Report 2024

The muscarinic acetylcholine receptor market has grown steadily in recent years. It will grow from $1.72 billion in 2023 to $1.8 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The expansion observed in the historical period can be attributed to several factors, including advancements in treating neurological disorders, improved management of cardiovascular conditions, therapies for ophthalmic disorders, treatments for respiratory conditions, and advancements in managing gastrointestinal disorders. These advancements likely contributed to growth within the field of muscarinic acetylcholine receptors and associated treatments during that time.

The muscarinic acetylcholine receptor market is expected to see steady growth in the next few years. It will grow to $2.19 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. Anticipated growth in the forecast period can be linked to several factors, including advancements in neuropharmacology, a rise in cases related to cardiovascular diseases, innovations in ophthalmic therapeutics, the emergence of new therapies for respiratory conditions, and an expanding pipeline of drugs for gastrointestinal disorders.

The escalating prevalence of neurological disorders is set to significantly drive the expansion of the muscarinic acetylcholine receptor market. These disorders, impacting the nervous system encompassing the brain, spinal cord, and peripheral nerves, find potential treatment targets in muscarinic acetylcholine receptors (mAChR), vital for regulating complex behaviors such as cognition and locomotion. Reports from The Neurological Alliance in September 2021 showed an increase in individuals awaiting neurology therapy, rising from 134,245 in May 2021 to 140,482 in June 2021. Additionally, the American Heart Association predicted a staggering rise in Alzheimer's disease and associated dementias, expected to affect 9.3 million individuals in the United States by 2060. This surge in neurological disorders is a significant driver of the muscarinic acetylcholine receptor market.

The growing awareness and diagnosis of glaucoma are expected to significantly boost the muscarinic acetylcholine receptor market. Glaucoma, a progressive eye disease damaging the optic nerve, often associates increased intraocular pressure with muscarinic acetylcholine receptors' role in regulating it. According to the BrightFocus Foundation in October 2022, about 2.7 million out of three million Americans aged 40 or older with glaucoma suffer from open-angle glaucoma, the most prevalent type. Globally, the glaucoma population is anticipated to reach over 111 million by 2040 from the current 80 million. This increased understanding of glaucoma's link to muscarinic receptors drives the market growth.

The upsurge in research and development initiatives is a pivotal trend shaping the muscarinic acetylcholine receptor market. Companies in this sector are intensifying development activities to fortify their market position. For example, in January 2022, researchers at Merck introduced MK-6884, a carbon-11-labeled molecule detecting the M4 subtype of muscarinic cholinergic receptors. This innovation aids in measuring drug efficacy and neuropathological receptor loss in conditions such as Alzheimer’s disease.

Major companies in the muscarinic acetylcholine receptor market are committed to innovating new products, seeking regulatory approval for schizophrenia treatment. Schizophrenia, a severe mental illness impacting thoughts, feelings, and behavior, often causes individuals to seem detached from reality. For instance, in September 2023, Karuna Therapeutics, Inc. submitted a New Drug Application (NDA) for KarXT (xanomeline-trospium) to the FDA for schizophrenia treatment. The company's dedication lies in pioneering innovative treatments for neurological and psychiatric illnesses, striving to address unmet medical needs.

In November 2021, Neurocrine Biosciences, Inc., a leading biopharmaceutical company based in the US, unveiled a strategic collaboration and licensing agreement with Sosei Group Corporation, a prominent pharmaceutical and biopharmaceutical company in Japan. The objective of this collaboration is to jointly develop novel muscarinic receptor agonists.

Major companies operating in the muscarinic acetylcholine receptor market report are Heptares Therapeutics Ltd., Sumitomo Dainippon Pharma Co. Ltd., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc., AstraZeneca plc, Karuna Pharmaceuticals Inc., Anven AlzDx Inc., Merck & Co Inc., Elsevier BV, Eurofins Discover X Corporation, Merck KGaA, Novus Biologicals LLC, Eli Lilly and Co., Novatein Biosciences Inc., Alomone Labs Ltd., GlaxoSmithKline plc, SK Bioscience Co., Johnson & Johnson, Pfizer Inc., Novartis AG, AbbVie Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Eisai Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sanofi SA, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the muscarinic acetylcholine receptor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global muscarinic acetylcholine receptor market during the forecast period. The regions covered in the muscarinic acetylcholine receptor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscarinic acetylcholine receptor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of muscarinic acetylcholine receptors include M1, M4, M5, among others. The M1 subtype is one of the five receptor subtypes involved in mediating the effects of acetylcholine. These receptors are G protein-coupled and participate in various physiological responses to acetylcholine. These receptors are accessible through different distribution channels such as hospitals, clinics, retail pharmacies, online pharmacies, and specialty centers. They find applications in several medical conditions such as chronic obstructive pulmonary disease, attention deficit hyperactivity disorder, Alzheimer's disease, memory impairment, psychiatric disorders, and more.

The muscarinic acetylcholine receptors market research report provides muscarinic acetylcholine receptors market statistics, including muscarinic acetylcholine receptors industry global market size, regional shares, competitors with a muscarinic acetylcholine receptors market share, detailed muscarinic acetylcholine receptors market segments, market trends and opportunities, and any further data you may need to thrive in the muscarinic acetylcholine receptors industry. This muscarinic acetylcholine receptors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. 

The muscarinic acetylcholine receptors market consists of sales of extracellular N-terminal segment, transmembrane domains (TM1-TM7), intracellular loops (IL1-IL3), intracellular C-terminal segment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.